Compare POWI & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWI | HRMY |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1997 | 2020 |
| Metric | POWI | HRMY |
|---|---|---|
| Price | $36.22 | $39.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $60.00 | $51.33 |
| AVG Volume (30 Days) | ★ 848.1K | 780.1K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | 0.32 | ★ 3.17 |
| Revenue | $445,550,000.00 | ★ $825,944,000.00 |
| Revenue This Year | $7.93 | $20.68 |
| Revenue Next Year | $7.60 | $15.93 |
| P/E Ratio | $114.85 | ★ $12.57 |
| Revenue Growth | 10.49 | ★ 21.13 |
| 52 Week Low | $30.86 | $25.52 |
| 52 Week High | $68.20 | $40.93 |
| Indicator | POWI | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 84.53 |
| Support Level | $32.81 | $32.77 |
| Resistance Level | $33.93 | $36.20 |
| Average True Range (ATR) | 1.32 | 1.21 |
| MACD | 0.70 | 0.36 |
| Stochastic Oscillator | 84.46 | 96.26 |
Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.